Open an account

Lantern Pharma

LTRN · NASDAQ

$0.6564+$0.0151 (+2.35%)TodayMarket closed ·
Prev close $0.6413

About LTRN

Lantern Pharma, Inc. engages in the development of drugs through leveraging artificial intelligence, machine learning, and genomic data. The company is headquartered in Dallas, Texas and currently employs 16 full-time employees. The company went IPO on 2020-06-11. The firm is developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, leverages over 100 billion oncology-focused data points and a library of over 200+ advanced ML algorithms to help solve problems in oncology drug development. The company is engaged in the development of its pipeline of therapies that span multiple cancer indications, including both solid tumors and blood cancers and an antibody drug conjugate (ADC) program. The company has active clinical programs for its three lead small molecule drug candidates: LP-300, LP-184, and LP-284. These programs are focused on multiple cancer indications, including both solid tumors and blood cancers. The company is also focused on the clinical execution of its therapies for CNS and brain cancers through Starlight Therapeutics Inc.

Employees
16
Headquarters
Dallas, Texas
Listed
Jun 11, 2020
Sector
Health Care
Industry
Biotechnology
Website
lanternpharma.com

LTRN key statistics

Market cap
9.80M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
303.14K
Volume
1.88M
Open price
$0.626
High today
$0.7501
Low today
$0.5982
52 Week high
$4.34
52 Week low
$0.625

Lantern Pharma (LTRN) at a glance

As of Oct 20, 2026, Lantern Pharma (LTRN) shares are priced at $0.6564, giving the company a market cap of 9.80M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.5982 and $0.7501. The current price is 9.7% above the day's low and 12.5% below its high.

Volume so far is 1.88M shares, above the average of 303.14K shares a day.

Over the past year Lantern Pharma has ranged from $0.625 to $4.34, and now sits 1% of the way up that range.

Lantern Pharma met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q2 FY26 it reported -$0.57 per share against an estimate of -$0.3876.

LTRN earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 20.3% on average.

  1. Q3 FY24: reported -$0.42 per share against an estimate of -$0.5712
  2. Q4 FY24: reported -$0.54 per share against an estimate of -$0.5202
  3. Q1 FY25: reported -$0.42 per share against an estimate of -$0.4998
  4. Q2 FY25: reported -$0.40 per share against an estimate of -$0.4947
  5. Q3 FY25: reported -$0.39 per share against an estimate of -$0.4794
  6. Q4 FY25: reported -$0.36 per share against an estimate of -$0.4692
  7. Q1 FY26: reported -$0.30 per share against an estimate of -$0.3672
  8. Q2 FY26: reported -$0.57 per share against an estimate of -$0.3876

LTRN news

  • Press releaseBusiness Wire

    Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 15th, 2026

  • Press releaseBusiness Wire

    Lantern Pharma Receives Taiwan Approvals to Open Next Stage of Phase 2 HARMONIC™ Trial of LP-300 in Never-Smoker, EGFR-Mutant NSCLC

  • Press releaseBusiness Wire

    Lantern Pharma Inc. Announces Closing of up to $8 Million Registered Direct Offering

  • Press releaseBusiness Wire

    Lantern Pharma Inc. Announces up to $8 Million Registered Direct Offering

  • Press releaseBusiness Wire

    Open-Medicine AI: Lantern Pharma to Present the Agentic AI Drug Development Market, User Needs, Development Roadmap, Platform Economics, and Benchmarks, Today at 12:30 PM ET

  • Press releaseBusiness Wire

    Lantern Pharma Secures USPTO Notice of Allowance for LP‑284 Treatment Patent in Aggressive B‑Cell Lymphomas

  • Lantern Pharma Q2 2026 Earnings Call: Complete Transcript

  • Press releaseBusiness Wire

    Lantern Pharma to Present Open-Medicine AI — a Multi-Agentic Platform for End-to-End Therapeutic Development — Business Model, Roadmap, and Value Proposition on September 23

Similar companies

Companies in the same industry as Lantern Pharma

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.